about
Offering aggregate results to participants in genomic research: opportunities and challengesPoints to consider: The research ethics consultation service and the IRBIRB chairs' perspectives on genotype-driven research recruitment.Recommendations for ethical approaches to genotype-driven research recruitment.Research Participants' Understanding of and Reactions to Certificates of Confidentiality.Research ethics. Certificates of confidentiality and compelled disclosure of dataImproving biobank consent comprehension: a national randomized survey to assess the effect of a simplified form and review/retest interventionDeveloping a simplified consent form for biobanking.Certificates of confidentiality and informed consent: perspectives of IRB chairs and institutional legal counsel.Ethical challenges in genotype-driven research recruitmentProspective biorepository participants' perspectives on access to research results.Managing incidental findings and research results in genomic research involving biobanks and archived data sets.Institutional review boards' use and understanding of certificates of confidentiality.Certificates of confidentiality: legal counsels' experiences with and perspectives on legal demands for research data.Considering the nature of individual research results.Ethical, legal, and social implications of biobanks for genetics research.Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working groupConfronting real time ethical, legal, and social issues in the Electronic Medical Records and Genomics (eMERGE) Consortium.Offering individual genetic research results: context matters.Informed consent for biobanking: consensus-based guidelines for adequate comprehension.Informed consent in genomics and genetic research.Simplifying informed consent for biorepositories: stakeholder perspectivesThe meaning of genetic research results: reflections from individuals with and without a known genetic disorder.Research participants' perspectives on genotype-driven research recruitment.Epilepsy patient-participants and genetic research results as "answers".Parent perspectives on pediatric genetic research and implications for genotype-driven research recruitmentCanadian Research Ethics Board Leadership Attitudes to the Return of Genetic Research Results to Individuals and Their FamiliesReturning a Research Participant's Genomic Results to Relatives: Analysis and Recommendations.Return of Genetic Research Results to Participants and Families: IRB Perspectives and RolesUse of altered informed consent in pragmatic clinical research.Am I a control?: Genotype-driven research recruitment and self-understandings of study participants.Changing perspectives on the benefits of newborn screening.Towards a more comprehensive understanding of cancer burden in North Carolina: priorities for interventionLessons from HeLa Cells: The Ethics and Policy of Biospecimens.Patients' Views Concerning Research on Medical Practices: Implications for Consent.Informed consent for biorepositories: assessing prospective participants' understanding and opinions.Pharmacogenetic testing in the face of unclear clinical efficacy: lessons from cytochrome P450 2D6 for tamoxifen.The effect of physician permission versus notification on research recruitment through cancer registries (United States).Research recruitment through US central cancer registries: balancing privacy and scientific issues.Ethical issues in identifying and recruiting participants for familial genetic research.
P50
Q28709472-608CFD6D-F85E-46A2-9436-D3EA2F56D026Q28762936-8E69F664-D1BF-4F1B-812C-AD82BBB927CFQ30539071-8C3A60DB-F113-4E37-8073-3D3D49F89A73Q30540771-89411F33-DD82-4941-857B-8CF953C6E4FCQ30572143-764CB903-C73F-4C13-92BB-0AAAC47EE592Q33384379-824A3FB2-D628-4EB5-9D4A-22F49EA7DDC1Q33563766-3649CD50-35C8-46DE-BFAF-575849AADC98Q33719347-EABB484C-7827-4F5F-9F71-512DEEB979F6Q33824967-19D7A25F-36C5-4B8C-BEDB-030E4B528C9FQ33881325-2F2726AD-522C-4C13-8759-510CEB22205EQ33941167-17BB5F70-3577-4138-99A3-6FF574C64FADQ34205284-C936D883-E2D8-4E4C-987A-3AF3FBB733C6Q34409785-C4AA0260-7E87-4EDF-B014-4BC159F59DADQ34453578-B1D7C388-DBE9-412F-A25B-9163E25D5162Q34579305-A5A33644-89D4-470E-A639-2458C68182EBQ34763998-F5462058-72AD-42B0-B1CD-895463FC60BCQ34960621-83A786B5-9F5D-49C4-A0FD-4D2542A1D28DQ34960752-81AAF82A-8A2B-49CD-8783-82EA47E31E46Q35106928-56CF9EC5-A6F7-49FF-8884-4A25EF81CA62Q35108262-F87AD6F0-99B9-4AA3-8585-92B4C5C16929Q35551797-8113C83F-D37D-42BF-9FF2-620C53DE5306Q35649408-3FF31C4F-2C27-41EB-A6F9-C5B769DBB5B8Q36066767-577E4499-B47C-4F92-886E-E42D44C2D0EEQ36090964-6A580FCC-7B28-4193-B85E-6DB6763EC12AQ36101366-6B11FAE7-B70C-49DA-85DC-25E677467F2AQ36185071-333DF2FF-8A38-4504-991D-2D4CA4EAFA5CQ36197067-87039B38-18AA-482F-B920-5C18D1BC6080Q36197112-C3916389-EF69-462D-B838-C8678006361AQ36198371-29A56320-4E73-4E07-8610-79DD65BECB92Q36397913-8A1B0EDB-6663-490B-9031-9DA2C59B8BB0Q36626526-75B4F5B5-4DA7-4180-AFDD-081191F763E3Q36689913-C8C9E94B-5965-4C26-B9F5-D8AE81D39351Q37346817-2F60423C-5362-4B2D-BD41-2FDD5917DACEQ37354569-BB0E4258-497F-4001-A79E-F3CC6C0FCEFCQ37376621-E8E9BF17-6279-409C-B5C7-CEE7FB7BBF8BQ40080444-23C96EA5-6ACC-418F-BE83-4A3E58DB7EECQ45962136-67802F93-109C-46C4-8FD9-F1FBF06D10B9Q50116205-75C1D38A-C2EB-4FC2-A0F0-9F945E81F116Q53251599-DE3E89C1-6691-420E-8F4B-F1933254A0FFQ53325910-8F4D4D54-4D37-482C-9C31-E5F6E394ADCC
P50
description
health policy researcher
@en
name
Laura M Beskow
@ast
Laura M Beskow
@nl
Laura Mari Beskow
@en
type
label
Laura M Beskow
@ast
Laura M Beskow
@nl
Laura Mari Beskow
@en
prefLabel
Laura M Beskow
@ast
Laura M Beskow
@nl
Laura Mari Beskow
@en
P21
P31
P496
0000-0002-9314-1915